PLAINSBORO, N.J. and BAGSVÆRD, Denmark, July 11, 2026 /PRNewswire/ -- Novo Nordisk today unveiled new data from the phase 3 FRONTIER4 extension study evaluating the long-term safety and efficacy of ...
Back in 2023, a council member said the council had “failed” to examine alternatives after repeated problems. Three years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results